$RGC Regencell Bioscience Additionally, to demonst
Post# of 44845
(Total Views: 184)
Posted On: 07/14/2022 9:16:28 AM
$RGC Regencell Bioscience Additionally, to demonstrate commitment to the Company, all directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Mr. Au further said, "I would like to also take this opportunity to also announce that I am currently spearheading a philanthropic project in my own capacity to provide grants to over 10,000 children afflicted with ADHD, ASD, COVID-19 and those in severe financial distress. I started providing grants on April 16, 2022 and have already helped over 150 children."
The timing, number and value of Ordinary Shares to be further purchased by Mr. Au, if any, will be determined by Mr. Au in his discretion and will depend on a variety of factors, including the market price of the Ordinary Shares, general market and economic conditions, available funds and applicable legal requirements.
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19. Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently in other markets as it deems appropriate. The Company has formed a joint venture to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
https://finance.yahoo.com/news/regencell-bios...00349.html
Mr. Au further said, "I would like to also take this opportunity to also announce that I am currently spearheading a philanthropic project in my own capacity to provide grants to over 10,000 children afflicted with ADHD, ASD, COVID-19 and those in severe financial distress. I started providing grants on April 16, 2022 and have already helped over 150 children."
The timing, number and value of Ordinary Shares to be further purchased by Mr. Au, if any, will be determined by Mr. Au in his discretion and will depend on a variety of factors, including the market price of the Ordinary Shares, general market and economic conditions, available funds and applicable legal requirements.
About Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19. Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients initially in Hong Kong and subsequently in other markets as it deems appropriate. The Company has formed a joint venture to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
https://finance.yahoo.com/news/regencell-bios...00349.html
(0)
(0)Scroll down for more posts ▼